Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605756 · ClinicalTrials.gov registry record · Phase 4
BOTOX Effects on Seizure Severity and Susceptibility
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT05605756: Clinical Trial Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
NCT05605756 is a Phase 4 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05605756, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research is to determine whether BOTOX injections will reduce seizure frequency and severity. We chose to test its effects on epilepsy because epilepsy and migraine have common features so, are often treated with common drugs.
Primary Outcome
TMS metrics of rMT, CSP, LICI, and TMS-EEG excitability metrics will each be averaged over at least 20 trials per subject per time block (at baseline, and 3 weeks and 8 weeks after BOTOX injections). Per metric mean values will then be compared by one-way repeated measures ANOVA.
Interventions
- DRUG OnabotulinumtoxinA 145 UNT [Botox]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 4 |
Why NCT05605756 stopped before completion
NCT05605756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which OnabotulinumtoxinA 145 UNT [Botox] is the first listed.
NCT05605756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05605756 about?
NCT05605756 is a clinical study titled "BOTOX Effects on Seizure Severity and Susceptibility". The purpose of this research is to determine whether BOTOX injections will reduce seizure frequency and severity. We chose to test its effects on epilepsy because epilepsy and migraine have common features so, are often treated with common drugs.
What is the current status of trial NCT05605756?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2023-03-01. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT05605756?
The interventions under investigation include: OnabotulinumtoxinA 145 UNT [Botox] (DRUG).
Who is sponsoring clinical trial NCT05605756?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05605756's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI